Close Menu

NCI

The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.

Lantern will use its AI platforms and NCI's omics datasets to identify and validate predictive genomic signatures for drugs it is developing.

Making a Mark

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.

The team will use a combination of genomics, pathology, and computer modeling to identify potential new therapeutic targets of the disease.

Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.

The team will create a group called the Extracellular RNA Communication Consortium Stage 2 to develop new EV-based technology and treat diseases.

ScienceInsider reports that researchers funded through the Cancer Moonshot program will have to make their papers immediately accessible to the public.

At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.

The software firm will use NGS data from patient biopsies to create molecular profiles and offer individualized cancer treatment recommendations.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.